Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring-Reference-Cited by-同舟云学术

Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring

Published:2022-07-06 Issue:9 Volume:97 Page:1236-1256
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:American J Hematol

Author:

Jabbour Elias¹^ORCID,Kantarjian Hagop¹^ORCID

Affiliation:

1. Department of Leukemia The University of Texas M. D. Anderson Cancer Center Houston Texas USA

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.26642

Reference160 articles.

1. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy

2. A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining

3. Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells

4. Factor independence of human myeloid leukemia cell lines is associated with increased phosphorylation of the proto‐oncogene Raf‐1;Okuda K;Exp Hematol,1994

Cited by 118 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Celastrol induces DNA damage and cell death in BCR-ABL T315I-mutant CML by targeting YY1 and HMCES;Phytomedicine;2024-11

2. Oxidative lipid damage by naringenin selectively sensitizes chronic myeloid leukemia cell lines and patient samples to Bcr-Abl tyrosine kinase inhibitors;Biochemical and Biophysical Research Communications;2024-11

3. Unraveling the secrets: Evolution of resistance mediated by membrane proteins;Drug Resistance Updates;2024-11

4. Natural compounds combined with imatinib as promising antileukemic therapy: An updated review;Fitoterapia;2024-10

5. Outcomes of chronic myeloid leukemia patients after therapeutic failure to conventional tyrosine kinase inhibitors and asciminib;Annals of Hematology;2024-09-13